Bristol-Myers Squibb Receives LEED® Silver Certification for its Biologics Manufacturing Facility in Devens, Massachusetts


DEVENS, Mass.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has received Leadership in Energy and Environmental Design (LEED®) Silver certification for its biologics manufacturing facility in Devens, Massachusetts. The laboratory and office building at the same facility received LEED Gold certification in December 2009.

LEED certification, established by U.S. Green Building Council and verified by the Green Building Certification Institute, is the nation’s preeminent program for the design, construction and operation of high performance green buildings.

“We are especially pleased to have received this recognition,” said Chris Perley, vice president and general manager of Bristol-Myers Squibb Devens operations.

“Our new facility, one of the largest of its kind in the world, demonstrates how Bristol-Myers Squibb is incorporating sustainability into its facilities and operations,” said Perley. “The company chose a former military base and consciously designed and constructed the facility in such a way to earn this distinction.”

To gain certification, the project used advanced energy modeling during the design. “Through the selection of high efficiency windows, insulation, and high efficiency motors, the manufacturing building is expected to consume 11 percent less energy compared to a building of similar size and use,” said Daniel Noberini, associate director of Environment, Health and Safety for the Devens operations.

If approved by the U.S. Food and Drug Administration (FDA) for commercial production in 2011, the Devens facility is expected to manufacture Orencia® (abatacept), the company’s first internally discovered biologic therapy for rheumatoid arthritis.

“For us, being green goes beyond meeting environmental mandates. Bristol-Myers Squibb is committed to reducing the impact of its operations on the environment,” said Susan Voigt, vice president for Environment, Health, Safety and Sustainability.

Some of the environmental highlights of the Devens facility include:

  • More than 30 percent of all building materials were manufactured using recycled materials.
  • During construction, 89 percent of construction and demolition waste was diverted from landfills and was processed for further recycling.
  • Redevelopment of a brownfield site.
  • The building has been designed to reduce water consumption by 46 percent compared to a building of similar size and use through the use of ultra-low flow lavatories, low-flow showers and janitor sinks.
  • No ozone-depleting substances are used in any of the building’s heating and cooling or fire suppression systems.
  • Preferred parking for low emitting (hybrid) and fuel efficient vehicles.
  • All paints, coatings, indoor adhesives and sealants used were low volatile organic compound (VOC) materials.
  • Native plantings in the landscaped areas reduce fertilization and water usage.
  • Non-manufacturing areas are cleaned with low VOC cleaners and will continue the site’s green commitment as part of its housekeeping program.

The laboratory and office building, awarded LEED Gold certification late last year, features no enclosed office spaces. As a result, 92 percent of all the work spaces receive natural light from the building’s large glass windows – an exemplary achievement which creates a pleasant work environment for employees. The “greenness” factor at Devens has also gained the attention of prospective employees who favor companies with strong sustainability programs.

LEED certification is the latest in a drumbeat of recognition for the company’s sustainability achievements and its commitment to the preservation of natural resources and efforts to minimize the environmental impact of its operations and products.

In September 2009, Newsweek named Bristol-Myers Squibb one of the greenest companies in America in the magazine’s first ever “Green Ranking” of the nation’s 500 largest companies, placing the company in eighth position.

Also in September, Dow Jones included Bristol-Myers Squibb in its annual Sustainability North America Index, a key reference for investors, while Corporate Responsibility Officers Magazine recognized the company as its “Best Corporate Citizen” for 2009 and ranked the company in seventh place for 2010.

About Bristol-Myers Squibb:

Bristol-Myers Squibb plans to submit the Devens site for U.S. FDA regulatory approval in late 2010 with approval for commercial production anticipated in the first half of 2011. Approval of the Devens facility would provide the company with the capability to support the production of biologic therapies. The company currently employs 250 people at its Devens facility. Construction of the Devens facility represents the single largest capital investment in the company’s history at $750 million.

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit

Bristol-Myers SquibbLinda Jordan,

Multimedia Files:

Categories: Press Releases